Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial.

The single exception was a marginally significant treatment by subgroup interaction for the subgroup of onset of asthma for FEV 1 AUC 0–6 ( p = 0.0463); however, this study was not powered to assess whether all subjects with more severe asthma and low lung function (FEV 1 <45 % predicted) would benefit from the regime.

also in 26,082 other papers